Azacitidine and lenalidomide combination: a novel relapse prophylaxis regimen after allogeneic hematopoietic stem-cell transplantation in patients with acute myeloid leukemia
- DOI
- 10.3389/fimmu.2023.1182251
- Published
- 2023-06-22
- Container
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.3389/fimmu.2023.1182251,
title = {Azacitidine and lenalidomide combination: a novel relapse prophylaxis regimen after allogeneic hematopoietic stem-cell transplantation in patients with acute myeloid leukemia},
author = {Yimei Feng and Ting Chen and Yun Zhang and Han Yao and Ping Wang and Lu Wang and Kaniel Cassady and Zhongmin Zou and Yuqing Liu and Lu Zhao and Lei Gao and Xi Zhang and Peiyan Kong},
year = {2023},
journal = {Frontiers in Immunology},
doi = {10.3389/fimmu.2023.1182251},
url = {https://doi.org/10.3389/fimmu.2023.1182251}
}RIS
TY - JOUR TI - Azacitidine and lenalidomide combination: a novel relapse prophylaxis regimen after allogeneic hematopoietic stem-cell transplantation in patients with acute myeloid leukemia AU - Yimei Feng AU - Ting Chen AU - Yun Zhang AU - Han Yao AU - Ping Wang AU - Lu Wang AU - Kaniel Cassady AU - Zhongmin Zou AU - Yuqing Liu AU - Lu Zhao AU - Lei Gao AU - Xi Zhang AU - Peiyan Kong PY - 2023 JO - Frontiers in Immunology DO - 10.3389/fimmu.2023.1182251 UR - https://doi.org/10.3389/fimmu.2023.1182251 ER -
APA
Feng, Y., Chen, T., Zhang, Y., Yao, H., Wang, P., Wang, L., Cassady, K., Zou, Z., Liu, Y., Zhao, L., Gao, L., Zhang, X., & Kong, P. (2023). Azacitidine and lenalidomide combination: a novel relapse prophylaxis regimen after allogeneic hematopoietic stem-cell transplantation in patients with acute myeloid leukemia. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2023.1182251
Source records
- crossref · retrieved 2026-09-25T18:18:55.071Z